Ovarian cancer drug olaparib 'can delay disease in newly diagnosed' A drug for advanced ovarian cancer has been approved for use in newly diagnosed patients in England, after a trial showed it could delay progression of the disease for three years.
Up to 600 women with a hereditary type of the disease could benefit each year. BBC News
See also:
Up to 600 women with a hereditary type of the disease could benefit each year. BBC News
See also:
- Game-changing ovarian cancer drug which extends survival by three years gets NHS green light The Daily Telegraph
- Game-changing ovarian cancer drug receives NHS approval The Independent
No comments:
Post a Comment